1. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.
- Author
-
Uzelac I, Iravanian S, Ashikaga H, Bhatia NK, Herndon C, Kaboudian A, Gumbart JC, Cherry EM, and Fenton FH
- Subjects
- Animals, Cardiac Pacing, Artificial, Coronavirus Infections drug therapy, Guinea Pigs, Heart diagnostic imaging, Rabbits, Tissue Culture Techniques, Voltage-Sensitive Dye Imaging, COVID-19 Drug Treatment, Antimalarials pharmacology, Heart drug effects, Heart physiopathology, Heart Rate drug effects, Hydroxychloroquine pharmacology
- Abstract
Background: Early during the current coronavirus disease 19 (COVID-19) pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only has the effectiveness of HCQ remained questionable, but mainly based on preclinical and a few small clinical studies, HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation., Objective: The purpose of this study was to investigate the arrhythmic effects of HCQ, as the heightened risk is especially relevant to COVID-19 patients, who are at higher risk for cardiac complications and arrhythmias at baseline., Methods: An optical mapping technique utilizing voltage-sensitive fluorescent dyes was used to determine the arrhythmic effects of HCQ in ex vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum dose of HCQ (1000 ng/mL)., Results: HCQ markedly increased action potential dispersion, resulted in development of repolarization alternans, and initiated polymorphic ventricular tachycardia., Conclusion: The study results further highlight the proarrhythmic effects of HCQ., (Copyright © 2020 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF